Search the Newsreel

Cellectar Biosciences (CLRB) ownership: Bleichroeder group reports 9.99% equity stake

Bleichroeder entities, led by Bleichroeder LP and Andrew Gundlach, have reported a 9.99% equity stake in Cellectar Biosciences (CLRB), amounting to 808,300 common shares. Bleichroeder LP, a registered investment adviser, holds these shares for various advisory clients, granting them sole voting and dispositive power …

Cellectar Biosciences Releases Q2 2026 Financial Results

Cellectar Biosciences (CLRB) reported a wider-than-expected diluted loss of $0.57 per share for Q2 2026, missing analyst estimates. Despite this, the net loss of $6.9M represents an 83.2% improvement year-over-year. The clinical-stage biopharmaceutical company maintains strong analyst support for its oncology pipeline.

Earnings call transcript: Cellectar narrows focus on WM as Q2 2026 loss widens

Cellectar Biosciences reported a wider-than-expected Q2 2026 loss of $0.57 per share, but its stock rose in premarket trading due to a stronger cash position and clinical progress for its lead drug, iopofosine I-131, in Waldenstrom’s macroglobulinemia (WM). The company secured up to $140 …

Cellectar Reports Q2 2026 Results, Strengthened Cash Positions Supports Oncology Pipeline

(RTTNews) - Cellectar Biosciences, Inc. (CLRB) reported second-quarter 2026 results, highlighting increased R&D investment and a stronger balance sheet compared to the prior year. The company advanced its oncology pipeline with progress in pivotal and early-stage trials, while preparing for a Phase 3 confirmatory …

Cellectar Biosciences (CLRB) Q2 loss hits $6.9M as cash reaches $34M

Cellectar Biosciences reported a net loss of $6.9 million for Q2 2026, an increase from $5.4 million in Q2 2025, driven by higher R&D expenses. The company's cash and cash equivalents rose to $34.0 million, up from $13.2 million at the end of 2025, …

Cellectar Prepares ~100-Patient-Per-Arm Trial, Plans 2027 FDA Filing

Cellectar Biosciences reported its Q2 2026 financial results, including a $6.9 million net loss, and provided significant corporate updates. The company is advancing its radiotherapeutic pipeline, most notably initiating site activation for a Phase 3 confirmatory trial for iopofosine I 131 in Waldenström macroglobulinemia, …

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Cellectar Biosciences announced its second-quarter 2026 financial results and provided a corporate update, highlighting progress in its oncology pipeline. Key developments include the initiation of site activation for a confirmatory Phase 3 study of iopofosine I 131 in Waldenström Macroglobulinemia (WM), with an NDA …

Cellectar Biosciences (CLRB) raises $31.7M, flags going concern risk

Cellectar Biosciences 6M 2026: Net loss $(12.6M), Diluted EPS $(1.52) — 10-Q Summary

Cellectar Biosciences reported a consolidated net loss of $(12.6M) and diluted loss per share of $(1.52) for the six months ended June 30, 2026. The company remains pre-revenue but achieved clinical milestones including positive Phase 2 results for CLOVER WaM and FDA Breakthrough Therapy …

Cellectar Biosciences Q2 2026 Earnings Preview

* Cellectar Biosciences (CLRB [https://seekingalpha.com/symbol/CLRB]) is scheduled to announce Q2 earnings results on Thursday, August 13th, before market open. * The consensus EPS Estimate is -$0.52 [https://seekingalpha.com/symbol/CLRB/earnings/estimates] (+84.7% Y/Y) and the consensus Revenue Estimate is $0M * Over the last 1 year, CLRB has …

Empery Asset Management, LP Initiates Position in Cellectar Biosciences Inc (CLRB)

Empery Asset Management, LP has initiated a new position in Cellectar Biosciences Inc (CLRB) by purchasing 864,090 shares, representing 2.81% of its portfolio. This investment reflects Empery's focus on small-cap healthcare companies, despite CLRB's significant stock decline and poor financial health. Cellectar Biosciences is …

Cellectar Biosciences Sets Major Conference Schedule: Pediatric Cancer Data Featured

Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company, announced its participation in five major medical and industry conferences throughout September 2025. COO Jarrod Longcor will present on the company's Phospholipid Drug Conjugate™ (PDC) platform, including its lead asset iopofosine I 131, with notable …

Cellectar Biosciences (CLRB) Sets Q3 2024 Earnings Call for Nov 18

Cellectar Biosciences (NASDAQ: CLRB) will report its third-quarter 2024 financial results and provide a corporate update on November 18, 2024, at 8:30 a.m. ET. Investors can access the conference call via a toll-free number or a webcast, with a replay available on the company's …

Cellectar BioSciences (CLRB.US) will release its earnings report before the market opens on August 13.

Cellectar BioSciences (CLRB.US) is scheduled to release its earnings report on August 13. The report will be published before the market opens.

Empery Asset Management (CLRB) discloses 9.99% beneficial stake via stock and warrants

Empery Asset Management, LP and Ryan M. Lane have reported a beneficial ownership of 9.99% in Cellectar Biosciences, Inc. (CLRB) through a Schedule 13G filing. This stake includes 864,090 shares, with 674,485 shares issuable upon the exercise of warrants, all subject to a 9.99% …

Cellectar Biosciences, Inc. Revenue Breakdown – NASDAQ:CLRB

This article provides a revenue breakdown for Cellectar Biosciences, Inc. (NASDAQ: CLRB) as presented on TradingView. It offers an overview of the company's financial data, including statements, statistics, dividends, earnings, and segment performance. The information is sourced from various financial data providers like ICE …

Cellectar Biosciences to Report Second Quarter 2026 Financial Results and Provide Corporate Update on August 13

Cellectar Biosciences, Inc. will report its second quarter 2026 financial results and provide a corporate update on August 13, 2026, at 8:30 a.m. Eastern Time. The company, which focuses on cancer drug development using its proprietary Phospholipid Drug Conjugate™ platform, has several drug candidates …

Cellectar Biosciences Inc (CLRB) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Cellectar Biosciences Inc (CLRB), noting its current valuation score of 7.10, which ranks 138 out of 155 in the Pharmaceuticals industry. The P/E ratio is reported at -0.46, though other key valuation metrics like P/B and P/CF …

CLRB|Cellectar Biosciences Inc|Price:2.500|Chg%:+0.080

This article provides a comprehensive stock analysis of Cellectar Biosciences Inc (CLRB) based on TradingKey's proprietary stock score. It highlights the company's strong fundamentals, high growth potential, and fair valuation within the Pharmaceuticals industry. The analysis also covers analyst ratings, institutional ownership, and risk …

Cellectar Biosciences Inc (CLRB) Institutional Confidence

This article from TradingKey focuses on the institutional confidence in Cellectar Biosciences Inc (CLRB). It provides the stock's current market data, including its price, market cap, and details institutional shareholdings and recent changes in their positions. The institutional confidence score is reported as 3.00, …

Cellectar Biosciences Inc (CLRB) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Cellectar Biosciences Inc (CLRB)'s historical dividends and stock splits. It notes that the company has not distributed any dividends in the past five years. However, it lists several stock split events, including a significant 30-to-1 merger split scheduled …

Cellectar Biosciences Inc (CLRB) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Cellectar Biosciences Inc (CLRB), identifying major shareholders like Hexstone Capital LLC and Bleichroeder LP, and categorizing shareholder types. It also provides a historical overview of institutional shareholding, showing the number of institutions and shares held over various …

Cellectar Biosciences Inc (CLRB) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a detailed risk assessment for Cellectar Biosciences Inc (CLRB), covering various metrics related to volatility, financial risk, and investment risk. It presents data on Beta, VaR, maximum drawdown, daily returns, Sharpe Ratio, realized volatility, and liquidity. The information aims to help …

Cellectar Biosciences Inc (CLRB) Income Statement

This article presents the quarterly and annual income statements for Cellectar Biosciences Inc (CLRB), offering a detailed look into its financial performance, including total revenue, operating expenses, and net income. It also provides answers to frequently asked questions about interpreting the income statement and …

Cellectar Biosciences Inc (CLRB) Cash Flow

This article provides a comprehensive overview of Cellectar Biosciences Inc.'s cash flow statements, including operating, investing, and financing activities, presented in detailed quarterly and annual data. It also includes key financial metrics for CLRB and answers frequently asked questions about different types of cash …

Cellectar Biosciences (CLRB) Proxy filing Summary

Cellectar Biosciences (CLRB) has scheduled its Annual Meeting for July 7, 2026, to be held virtually, with stockholders of record as of May 19, 2026, eligible to vote. Key proposals include the election of two Class III directors, an increase in shares for the …

Cellectar Biosciences (CLRB) Q1 2026 earnings summary

Cellectar Biosciences reported a transformational Q1 2026, driven by positive 12-month data from the CLOVER-WaM study for iopofosine I-131, which supports plans for accelerated FDA approval. The company also secured up to $140 million in financing and dosed the first patients in a trial …

Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate radiotherapy pipeline, led by iopofosine I-131 in Waldenstrom macroglobulinemia

Cellectar BioSciences has published a corporate presentation detailing its phospholipid drug conjugate radiotherapy pipeline, highlighting iopofosine I-131 for Waldenström macroglobulinemia. The company plans to seek US accelerated approval for iopofosine I-131 in the first half of 2027, with a Phase 3 confirmatory trial projected …

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

Cellectar Biosciences announced the publication of results from its Phase 1 dose-escalation study of iopofosine I 131 in combination with low-dose dexamethasone for relapsed/refractory multiple myeloma in the journal *Cancers*. The study showed a favorable safety profile with manageable toxicity and promising preliminary clinical …

Cellectar publishes phase 1 data on multiple myeloma treatment

Cellectar Biosciences Inc. announced positive Phase 1 study results for iopofosine I 131 combined with low-dose dexamethasone in relapsed/refractory multiple myeloma patients. The study showed manageable toxicity, encouraging disease control, and antitumor activity, with an overall response rate of 15.4% and 30% in a …

Cellectar Myeloma Data: 84.6% of 26 Evaluable Patients Stable or Better

Cellectar Biosciences announced the publication of Phase 1 study results for iopofosine I 131 with low-dose dexamethasone in heavily pretreated relapsed/refractory multiple myeloma patients in the peer-reviewed journal Cancers. The study showed that 84.6% of 26 evaluable patients achieved stable disease or better, with …